Author’s response to reviews

Title: Comparing the efficacy of targeted spinal cord stimulation (SCS) of the dorsal root ganglion with conventional medical management (CMM) in patients with chronic post-surgical inguinal pain: The SMASHING trial

Authors:

Frederique Mol (frederique.mol@mmc.nl)
Rudi Roumen (r.roumen@mmc.nl)
Marc Scheltinga (m.scheltinga@mmc.nl)

Version: 1 Date: 23 Mar 2017

Author’s response to reviews:

Rotterdam, 22-MAR-2017

Dear editor,

Thank you for your suggestions regarding our manuscript "Comparing the efficacy of targeted spinal cord stimulation (SCS) of the dorsal root ganglion with conventional medical management (CMM) in patients with chronic post-surgical inguinal pain: The SMASHING trial" (BSUR-D-17-00070).

We are pleased to inform you the “Declarations section” has been added to the manuscript. Furthermore, we have sent copies of all the original ethical approval documents (funding approval was not applicable in our case) to BMCSeriesEditorial@biomedcentral.com. Unfortunately the English translations have been delayed. I expect to be able to forward these to you next week and I hope this is not a problem.

Our study has indeed received funding from a commercial organization (Spinal Modulation Inc. now St. Jude Medical/Abbott, Illinois, USA) and as such has not been peer-reviewed by a funding body. We have now clearly stated this information in the 'competing interests' section of our manuscript.
The article that was found in the ‘related article search’ concerns an announcement of the study in a well-read Dutch general medical topics journal, with the sole purpose to inform surgeons and pain specialists that eligible patients could be referred to our center for participation in the study. The current study status is ‘ongoing’: there is still data being collected and analyzed.

We hope this answers all your queries.

Kind regards,

Frédérique Mol,
Phd Candidate Surgery dept.
Erasmus MC, Rotterdam / Maxima Medical Center, Eindhoven
The Netherlands